vib4920
mAbexperimental
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Aug 30, 2019 (NCT04046549)
Timeline
Indications
Mechanism of action
- CD40 ligandANTAGONIST
CD40 ligand antagonist
- CD40 ligandINHIBITOR
CD40LG inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594331 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06747949 | Phase 3 | Jan 27, 2025 | Amgen |
| NCT06245408 | Phase 3 | Mar 11, 2024 | Amgen |
| NCT06104124 | Phase 3 | Oct 26, 2023 | Horizon Therapeutics, LLC |
| NCT05306353 | Phase 2 | Dec 1, 2022 | Duke University, Immune Tolerance Network, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05201469 | Phase 2 | May 16, 2022 | Feinstein Institute for Medical Research, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco |
| NCT04174677 | Phase 2 | Dec 31, 2019 | Viela Bio |
| NCT04163991 | Phase 2 | Dec 2, 2019 | Viela Bio |
| NCT04129164 | Phase 2 | Oct 16, 2019 | Viela Bio |
| NCT04046549 | Phase 2 | Aug 30, 2019 | Viela Bio |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Viela Bio | For profit | 4 | 4 | 1 | 2019 |
| Amgen | For profit | 2 | 2 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2022 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Feinstein Institute for Medical Research | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Horizon Therapeutics, LLC | For profit | 1 | 1 | 1 | 2023 |
| Immune Tolerance Network | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1